Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1994 Apr 28;330(17):1185-91.
doi: 10.1056/NEJM199404283301703.

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

E B Papadopoulos  1 , M Ladanyi, D Emanuel, S Mackinnon, F Boulad, M H Carabasi, H Castro-Malaspina, B H Childs, A P Gillio, T N Small, et al.
Affiliations
Free article
Case Reports

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

E B Papadopoulos et al. N Engl J Med. .
Free article

Abstract

Background: Lymphoma associated with Epstein-Barr virus (EBV) is a complication of bone marrow transplantation that responds poorly to standard forms of therapy. The lymphoma is usually of donor origin. We hypothesized that treatment with infusions of donor leukocytes, which contain cytotoxic T cells presensitized to EBV, might be an effective treatment.

Methods: We studied five patients in whom EBV-associated lymphoproliferative disorders developed after they received a T-cell-depleted allogeneic bone marrow transplant. Biopsy specimens were immunophenotyped, subjected to the polymerase chain reaction to determine the origin of the lymphoma (donor or host) and to detect the presence of EBV, and analyzed by Southern blotting for the presence of the clonal EBV genome and immunoglobulin-gene rearrangement. Patients were treated with infusions of unirradiated donor leukocytes at doses calculated to provide approximately 1.0 x 10(6) CD3+ T cells per kilogram of body weight.

Results: Histopathological examination of biopsy specimens from all five patients demonstrated monomorphic, malignant lymphomas of B-cell origin. Each of the four specimens that could be evaluated was of donor-cell origin. Evidence of clonality was found in two of the three samples adequate for study. EBV DNA was detected by the polymerase chain reaction in all five samples. In all five patients there were complete pathological or clinical responses. The responses were first documented histologically within 8 to 21 days after infusion. Clinical remissions were achieved within 14 to 30 days after the infusions and were sustained without further therapy in the three surviving patients for 10, 16, and 16 months.

Conclusions: In a small number of patients, infusions of unirradiated donor leukocytes were an effective treatment for EBV-associated lymphoproliferative disease that arose after allogeneic bone marrow transplantation.

PubMed Disclaimer

Comment in

  • Donor T cells to treat EBV-associated lymphoma.
    Heslop HE, Brenner MK, Rooney CM. Heslop HE, et al. N Engl J Med. 1994 Sep 8;331(10):679-80. doi: 10.1056/NEJM199409083311017. N Engl J Med. 1994. PMID: 8052285 No abstract available.
  • Using T cells to treat B-cell cancers.
    Lieberman J, Buchsbaum RJ. Lieberman J, et al. N Engl J Med. 1994 Apr 28;330(17):1231-3. doi: 10.1056/NEJM199404283301711. N Engl J Med. 1994. PMID: 8139635 No abstract available.

Publication types

MeSH terms

LinkOut - more resources